The role of a cardio-oncology clinical nurse specialist in the United Kingdom

Figures

• 

  Fig. 1. Cardiovascular toxicities of cancer therapies.4 TKIs, tyrosine kinase inhibitors; ICIs, Immune checkpoint inhibitors.

• 

  Fig. 2. Model of RBH Cardio-Oncology centre of excellence. RBH, Royal Brompton Hospital.

• 

  Fig. 3. The CTR-CVT risk is the combination of the likelihood (based on reported incidence) and degree (severity or grade) of the adverse event.1 CTR-CVT, cancer therapy-related cardiovascular toxicity.

• 

  Fig. 4. Patient information leaflet: Red Flags to look out for during cancer treatment, this is discussed during the initial consultation with the patient and all information is in the clinic letter.

• 

  Fig. 5. Management at home: Patient information leaflet for patients to know what they should be monitoring at home; this is discussed during the initial consultation with the patient following referral.